ImmuneOnco Biopharmaceuticals (Shanghai) Co.,Ltd., founded in June 2015 in Zhangjiang High-Tech Park of Shanghai, China, is an early-stage biopharmaceutical company dedicated to development and commercialization of novel cancer immunotherapeutics that reverse cancer cell-induced immune inhibition and actively eradicate cancer cells.
To achieve these goals, we have established several proprietary platforms harnessing two types of innate immune cells, macrophages and natural killer (NK) cells, to fulfill the cancer-killing tasks. Macrophages play critical roles in fighting cancer through phagocytosis followed by tumor antigen presentation to T cells, which in turn destroy antigen-expressing tumor cells. However, cancer cells have evolved to evade immune surveillance, by mechanisms such as over-expressing CD47 and inhibiting phagocytosis via interaction with signal regulatory protein (SIRPα) on macrophages. We are developing a pipeline of compounds for reversing cancer cell-induced inhibition of innate immunity.
NK cells are innate defense mechanisms of the body against viral infection and cancer, which directly target pathogenic cells without requirement for MHC recognition. We have established proprietary platforms and target-activated NK (TANK™) cell therapy for treatment of both leukemia and solid tumors.
ImmuneOnco is actively advancing pipelines of proprietary platform-based compounds targeting a broad range of canncer indications.